TY - JOUR T1 - Dr. Charles-Schoeman and E. Bananis Reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 1605 LP - 1605 DO - 10.3899/jrheum.180489 VL - 45 IS - 11 AU - CHRISTINA CHARLES-SCHOEMAN AU - EUSTRATIOS BANANIS Y1 - 2018/11/01 UR - http://www.jrheum.org/content/45/11/1605.2.abstract N2 - To the Editor:We thank Professor Boers for his interest1 in our study2 and are grateful for the opportunity to respond to his queries.Our posthoc analysis investigated the effect of concomitant glucocorticoid (GC) use on clinical and radiographic outcomes in phase III studies of methotrexate (MTX)-naive patients receiving tofacitinib or MTX as monotherapy (ORAL Start), disease-modifying antirheumatic drug (DMARD)–inadequate responder (IR) patients receiving tofacitinib or placebo as monotherapy (ORAL Solo), and MTX-IR and DMARD-IR patients receiving tofacitinib or placebo in combination with background conventional synthetic DMARD (ORAL Sync, ORAL Standard, ORAL … Address correspondence to E. Bananis, 235 E. 42nd St., New York, New York 10017, USA. E-mail: stratis.bananis{at}pfizer.com. ER -